Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protein Protein Interaction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Protein Protein Interaction. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-023189-27 Sponsor Protocol Number: RG-10-179 Start Date*: 2011-01-20
    Sponsor Name:University of Birmingham
    Full Title: The pharmacogenetics of vitamin D response in tuberculosis
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006948-65 Sponsor Protocol Number: Version 4 Start Date*: 2007-11-29
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: The effect of acidosis correction and exercise on tissue wasting and immune function in renal patients
    Medical condition: Chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-005004-26 Sponsor Protocol Number: ARC010 Start Date*: 2017-04-12
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS)
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) ES (Completed) SE (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006953-41 Sponsor Protocol Number: C08-002B Start Date*: 2009-08-19
    Sponsor Name:ALEXION PHARMACEUTICALS, INC.
    Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)
    Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapyresistant Atypical Hemolytic-Uremic Syndrome (aHUS).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018932 Haemolytic uraemic syndrome LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002387-32 Sponsor Protocol Number: UoL001019 Start Date*: 2014-08-05
    Sponsor Name:University of Liverpool
    Full Title: Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis
    Medical condition: Aminoglycoside-induced nephrotoxicity
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    18.0 10022891 - Investigations 10069022 Kidney injury molecule-1 PT
    18.0 100000004857 10067571 Nephrotoxicity LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002186-17 Sponsor Protocol Number: volgt Start Date*: 2021-08-31
    Sponsor Name:RadboudUMC
    Full Title: Timing and sequence of vaccination against COVID-19 and Influenza
    Medical condition: Immunogenicity of the consecutive vaccination with both an mRNA COVID-19 vaccin and Influenza vaccin, in different sequences
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-006118-19 Sponsor Protocol Number: 2020-012-00EU1 Start Date*: 2021-06-29
    Sponsor Name:HUTCHMED Limited
    Full Title: An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe
    Medical condition: Neuroendocrine Tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Ongoing) IT (Ongoing) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2008-006952-23 Sponsor Protocol Number: C08-002A Start Date*: 2009-08-19
    Sponsor Name:ALEXION PHARMACEUTICALS, INC.
    Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)
    Medical condition: Adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018932 Haemolytic uraemic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006954-17 Sponsor Protocol Number: C08-003A Start Date*: 2009-06-18
    Sponsor Name:ALEXION PHARMACEUTICALS, INC.
    Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
    Medical condition: Adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018932 Haemolytic uraemic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003488-71 Sponsor Protocol Number: OVG-2013/04 Start Date*: 2013-12-12
    Sponsor Name:University of Oxford
    Full Title: A pilot study of the impact of BCG administration on the immunogenicity of serogroup C meningococcal conjugate vaccine in healthy infants
    Medical condition: Vaccine responses
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001109-22 Sponsor Protocol Number: PBGM01-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Passage Bio, Inc.
    Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su...
    Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006955-28 Sponsor Protocol Number: C08-003B Start Date*: 2009-08-19
    Sponsor Name:ALEXION PHARMACEUTICALS, INC.
    Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
    Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapysensitive Atypical Hemolytic-Uremic Syndrome (aHUS).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018932 Haemolytic uraemic syndrome LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001334-26 Sponsor Protocol Number: ARC008 Start Date*: 2018-01-17
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended) SE (Completed) ES (Completed) DE (Completed) FR (Prematurely Ended) NL (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002938-20 Sponsor Protocol Number: AIO-STO-0218 Start Date*: 2019-03-27
    Sponsor Name:Charite - Universitätsmedizin Berlin
    Full Title: Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO
    Medical condition: metastatic gastro-oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004799-50 Sponsor Protocol Number: PNEUMOREG Start Date*: 2015-02-13
    Sponsor Name:Federico Martinon Torres
    Full Title: Evaluation of the immunoregulatory role of pneumococcal conjugate vaccination in pediatric patients with allergic asthma or type 1 diabetes mellitus versus pediatric population control.
    Medical condition: Allergic asthma and type 1 diabetes mellitus in pediatric subjects.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001742-13 Sponsor Protocol Number: 06_RADIO_56 Start Date*: 2006-10-04
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: Locally Advanced Pancreatic Cancer: Phase II study of cetuximab and 3-D conformal image-guided radiotherapy (PACER Study)
    Medical condition: Adenocarcinoma of the pancreas which is locally advanced/inoperable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002154-32 Sponsor Protocol Number: AT2220-010 Start Date*: 2011-12-07
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: AN OPEN-LABEL MULTI-CENTER, INTERNATIONAL STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT2220 AND ALGLUCOSIDASE ALFA IN PATIENTS WITH POMPE DISEASE
    Medical condition: Pompe Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10036143 Pompe's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002930-19 Sponsor Protocol Number: XBR1001 Start Date*: 2019-02-25
    Sponsor Name:Xbrane Biopharma
    Full Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Wet Age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) HU (Completed) SK (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-000985-31 Sponsor Protocol Number: RALAM-II Start Date*: 2017-10-04
    Sponsor Name:Fundació Clinic per a la Recerca Biomédica
    Full Title: Phase 3b, single arm, single site simplification study with dual therapy including 3TC (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected atients experiencing inco...
    Medical condition: Virologically suppressed Human Immunodeficiency Virus-1 infected patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020168 10020445 Human immunodeficiency virus type I infection with constitutional disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000121-32 Sponsor Protocol Number: 68284528MMY2001 Start Date*: 2019-09-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA